Arabic Arabic English English French French German German
dark

Vaccitech to Present at the Jefferies London Healthcare Conference

OXFORD, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that Bill Enright, Chief Executive Officer, will be presenting at the Jefferies London Healthcare Conference.

   
Event: Jefferies London Healthcare Conference
Presentation: In person and webcast fireside chat
Date: November 17
Time:
Webcast:
8 a.m. GMT (3 a.m. EST)
Events section of the Vaccitech website
   
   

An audio webcast of each presentation can be accessed through the Events section of the Company’s website at https://investors.vaccitech.co.uk/news-and-events/events. An archived replay of each webcast will also be available on the Company’s website.

About Vaccitech plc
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

Vaccitech Media contacts:
Katja Stout, Scius Communications (EU)
Direct: +44 (0) 7789435990
Email: katja@sciuscommunications.com

Robert Flamm, Ph.D. / Harrison Wong, Burns McClellan, Inc. (US)
212-213-0006 ext. 364 / 316
Email: rflamm@burnsmc.com / hwong@burnsmc.com

Henry Hodge, Vaccitech
Email: henry.hodge@vaccitech.co.uk

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Dispelling 3 of the Most Persistent Myths About Modern Hearing Aids

Next Post

Genome Damage Drives Telomere-Induced Cellular Aging

Related Posts
Total
0
Share